• Dextran Sulfate Sodium Salt: Advancing IBD Mouse Models

  2026-06-29

  Dextran sulfate sodium salt (MW 35000-45000) enables high-fidelity modeling of intestinal inflammation and epithelial repair, crucial for ulcerative colitis research. Leveraging breakthrough insights into GPR35-KLF5 signaling, this product from APExBIO empowers experimental workflows that drive preclinical discovery.

• Revisiting Sumatriptan Metabolism: CYP and MAO Pathway Insig

  2026-06-29

  This article examines the recent re-evaluation of sumatriptan metabolism, demonstrating that cytochrome P450 enzymes, in addition to monoamine oxidase A, contribute to its biotransformation. These findings refine our understanding of drug metabolism critical to neurodegenerative and CNS research models.

• LPS Maintains Hepatocyte Stemness via YAP1: Mechanistic Insi

  2026-06-28

  Shao et al. (2021) uncover that high levels of lipopolysaccharide (LPS) in the portal vein sustain the stemness of hepatocytes by activating YAP1 signaling. Their work reveals a direct mechanistic link between LPS/TLR4/YAP1 axis and hepatic progenitor potential, with implications for liver regeneration and cellular reprogramming.

• Microbiota–Tryptophan–AhR Axis Drives ISC Repair in Colitis

  2026-06-27

  Li et al. elucidate how Huangqin decoction (HQD) repairs ulcerative colitis by remodeling the gut microbiota, enhancing microbial tryptophan metabolism, and activating AhR-mediated intestinal stem cell differentiation. Their integrative approach defines a microbiota–tryptophan–AhR–ISC axis as a promising therapeutic target for mucosal regeneration in inflammatory bowel disease.

• α-Bungarotoxin: Precision Nicotinic Receptor Blockade Workfl

  2026-06-26

  α-Bungarotoxin is revolutionizing neuroscience and placental research through highly selective nicotinic receptor blockade. This guide details advanced experimental workflows, troubleshooting, and protocol optimization—empowering researchers to achieve rigorous, reproducible results with APExBIO’s validated reagent.

• Trilaurin (Glycerol Tridodecanoate) in Lipid-Based Drug Deli

  2026-06-26

  Trilaurin offers unmatched reproducibility as a lipid excipient for solid lipid microparticle and nanoparticle platforms, enabling precise protocols for biocatalytic synthesis and oral delivery of challenging peptide/protein drugs. Recent studies clarify its unique non-adjuvant immunological profile, guiding optimal use in both formulation science and immunotoxicology.

• Liproxstatin-1: Strategic Inhibition of Ferroptosis for Tran

  2026-06-25

  Explore the mechanistic foundation and translational promise of Liproxstatin-1 as a potent ferroptosis inhibitor. This thought leadership article delivers actionable guidance for researchers, integrating mechanistic advances, protocol insights, and clinical perspectives, with a focus on enhanced experimental rigor and future directions in ferroptosis research.

• Decoding Mucosal Repair: DSS Models and the GPR35-KLF5 Axis

  2026-06-25

  Explore how Dextran sulfate sodium salt (MW 35000-45000) drives innovation in ulcerative colitis research by enabling mechanistic studies of intestinal epithelial repair via the GPR35-KLF5 circuitry. This thought-leadership article bridges advanced biological insight with practical experimental guidance, offering strategic recommendations for translational teams leveraging DSS-induced colitis models.

• Dextrose (D-glucose): Redefining Immunometabolism Research

  2026-06-24

  This article explores the mechanistic and strategic value of Dextrose (D-glucose) in modeling tumor microenvironment dynamics, with a focus on hypoxia-driven metabolic reprogramming and immunometabolic competition. Integrating recent evidence and experimental best practices, we offer actionable guidance for translational researchers seeking to leverage D-glucose as a cornerstone reagent, while distinguishing this discussion from conventional product summaries.

• (+)-Bicuculline: Technical Use and Workflow Guidance

  2026-06-23

  (+)-Bicuculline is a competitive GABAA receptor antagonist widely used to dissect inhibitory neurotransmission and modulate synaptic NMDA receptor signaling in neuroscience research. It is not suitable for clinical or diagnostic use and requires strict attention to solubility, storage, and workflow handling for experimental reliability.

• CD28-ARS2 Axis Drives PKM Splicing for CD8+ T Cell Metabolic

  2026-06-23

  This study uncovers a novel CD28-ARS2 signaling axis that regulates alternative splicing of pyruvate kinase (PKM) in CD8+ T cells, promoting metabolic flexibility crucial for antitumor immunity. The findings highlight posttranscriptional control of glucose metabolism as a key determinant of T cell effector function, with implications for immunometabolic research.

• Spiroplasma eriocheiris Entry: Cytoskeletal Dependencies in

  2026-06-22

  This study defines the cellular entry mechanisms of Spiroplasma eriocheiris into Drosophila S2 cells, demonstrating reliance on clathrin-mediated endocytosis and macropinocytosis, as well as the critical roles of actin and microtubules. These insights refine models for host-pathogen interaction studies in invertebrate systems and highlight the utility of actin-modulating research tools.

• Perifosine (KRX-0401): Applied Protocols for Apoptosis and A

  2026-06-22

  Perifosine (KRX-0401) stands out as a synthetic alkylphospholipid Akt inhibitor, enabling precise modulation of apoptosis and radiosensitization workflows. Explore optimized experimental protocols, comparative applications, and troubleshooting strategies that elevate research targeting Akt/mTOR signaling and apoptosis in cancer and neuroprotection models.

• Midecamycin: Optimizing Gram-Positive Bacterial Inhibition W

  2026-06-21

  Midecamycin, an acetoxy-substituted macrolide antibiotic, offers precise, robust inhibition of Gram-positive bacteria, making it a valuable tool for advanced antibacterial research. This article delivers actionable, workflow-focused guidance to maximize assay reproducibility and troubleshoot resistance, drawing on real-world experimental scenarios and the latest reference findings.

• Strategic TAK1 Inhibition: (5Z)-7-Oxozeaenol for Antioxidant

  2026-06-20

  (5Z)-7-Oxozeaenol, a potent TAK1 inhibitor, is reshaping translational inflammation and cancer research by enabling precise modulation of NF-κB and MAPK signaling. This thought-leadership article synthesizes recent mechanistic discoveries—especially the AMPK–SQSTM1 feedback loop in metabolic stress adaptation—offering strategic guidance for researchers designing next-generation models that bridge inflammation, redox regulation, and tumor adaptation. We position (5Z)-7-Oxozeaenol, as supplied by APExBIO, at the forefront of this paradigm shift, with actionable protocols and an outlook grounded in the latest evidence.

450 records 13/30 page Previous Next First page 上5页 1112131415 下5页 Last page